Open AccessHearing and Vestibular Loss with Misuse of Opioids and Illicit Drugs: A Review of the Literature
Author(s) -
Michelle L. Hughes,
Amanda Rodriguez,
Jonathan L. Hatch,
Kenneth Zoucha
Publication year - 2022
Publication title -
audiology and neuro-otology
Language(s) - English
Resource type - Journals
eISSN - 1421-9700
pISSN - 1420-3030
DOI - 10.1159/000521965
Subject(s) - medicine , heroin , retrospective cohort study , hearing loss , medical prescription , methadone , drug , psychiatry , pharmacology , audiology
Background: The purpose of this review was to summarize the literature regarding the effects of opioids and illicit drugs on the auditory and vestibular systems. Methods: Data were sourced from published papers reporting hearing loss (HL) and/or vestibular loss (VL) following misuse or overdose of opioids or illicit drugs. Most papers consisted of retrospective single-case reports, with few retrospective reviews or prospective cohort studies. Search terms included variations of HL, VL, opioids, and illicit drugs. Search results yielded 51 articles published between 1976 and 2021. A total of 44 articles were reviewed after excluding studies that were not available in English ( n = 3), only described acute effects in healthy cohorts ( n = 3) or only described general health aspects in a group on methadone maintenance ( n = 1). Results: Sixteen studies reported ototoxicity from illicit drugs, 27 from prescription opioids, and 1 was unspecified. This review shows that HL associated with amphetamines and cocaine was typically sudden, bilateral, and temporary. HL from cocaine/crack and heroin often presented with greatest losses in the mid-frequency range. HL associated with opioids was typically sudden, bilateral, moderately severe to profound, and in most cases permanent. The literature is sparse regarding VL from illicit drugs and opioids. Conclusion: Practitioners who see patients for sudden or rapidly progressive HL or VL with no apparent cause should inquire about misuse of illicit drugs and opioids, particularly when the HL does not respond to steroid treatment.